Immersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Glimpse Group Inc
VRAR
Current price
$1.34
Provides enterprise-focused virtual and augmented reality software and services across various industries, including the healthcare sector for therape...
Provides enterprise-focused virtual and augmented reality software and services across various industries, including the healthcare sector for therapeutic solutions.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
These companies represent the exciting intersection of healthcare and cutting-edge technology. By focusing on businesses developing VR/AR platforms for rehabilitation, pain management, and psychological treatment, this collection targets a high-growth niche that's gaining momentum through increasing FDA approvals and clinical adoption.
What You Need to Know
This group offers exposure to the rising demand for non-pharmacological, data-driven therapies that can be personalized to patient needs. As digital therapeutics gain insurance reimbursement and broader acceptance from medical institutions, these pioneering companies are well-positioned to capture significant market growth.
Why These Stocks
We've handpicked companies with demonstrated expertise in medical VR/AR hardware, haptic technology, and specialized software cleared for clinical use. Each selection represents a different aspect of the immersive therapy ecosystem, from the technology creators to those already implementing solutions in healthcare settings.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+425.08%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 425.08% over the next year.
Stocks Rated Buy by Analysts
12 of 12 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Medical Revolution Happening Now
VR/AR therapy is gaining rapid clinical acceptance and FDA approvals, creating a perfect entry point for investors before mainstream adoption fully takes hold.
Beyond Traditional Medicine
These companies offer an alternative to pharmaceutical approaches with fewer side effects, tapping into growing patient demand for non-invasive, personalized treatment options.
Multiple Growth Catalysts Ahead
Expanding insurance reimbursement, increasing clinical adoption, and a growing body of efficacy research are all converging to potentially accelerate this sector's growth.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.